[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334242-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334242-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","multiomics-analysis-of-homologous-recombination-deficiency-across-cancer-types-research-focus","Multiomics analysis of homologous recombination deficiency across cancer types - Research focus","","Ongoing debate surrounds how homologous recombination deficiency (HRD) relates to patient survival across malignancies, requiring a comprehensive, multi-cancer view. Using multivariable omics data from databases, the study analyzes HRD across 33 cancer types, emphasizing 23 cancers where HRD associates with overall survival. Mechanistic links to prognosis are assessed through gene expression, gene mutation, DNA methylation, and signaling pathways, together with correlations to immune cell infiltration and clinical stage or tumor grade. Results show HRD significance but cancer-dependent effects, including distinct tumor subtype outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/multiomics-analysis-of-homologous-recombination-deficiency-across-cancer-types-research-focus/334242/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/multiomics-analysis-of-homologous-recombination-deficiency-across-cancer-types-research-focus/334242.png","ImageObject",300,407,{"name":42,"@type":43},"Clementine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the study aim to clarify about homologous recombination deficiency (HRD)?","Question",{"text":63,"@type":64},"It evaluates the association between HRD and patient overall survival across multiple cancer types, addressing uncertainty in existing findings and the need for a comprehensive cross-cancer understanding.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which omics layers and biological aspects are analyzed in relation to HRD?",{"text":68,"@type":64},"The analysis integrates gene expression, gene mutation, differentially methylated regions, and signaling pathway correlations, and it also examines immune cell infiltration patterns.",{"name":70,"@type":61,"acceptedAnswer":71},"How do the effects of HRD differ across cancers and tumor subtypes?",{"text":72,"@type":64},"HRD is significantly linked to prognosis overall, but its impact varies by cancer type, and outcomes differ across tumor subtypes; HRD also correlates with clinical stage and tumor grade.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334242,1790167573,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","RESEARCH ARTICLE  \nMultiomics analysis of homologous recombination deficiency across cancer types  \nLin Dong 1\\#, Lin Li2\\#, Linyan Zhu1, Fei Xu1, 3, Rumeng Zhang1, Qiushuang Li4, Yong Zhu4, Zhutian Zeng5, 6 ∗, and Keshuo Ding 1, 7 ∗  \nThere remains ongoing debate regarding the association of homologous recombination deficiency (HRD) with patient survival across various malignancies, highlighting the need for a comprehensive understanding of HRD’s role in different cancer types. Based on data from databases, we conducted a multivariable omics analysis on HRD in 33 cancer types, focusing mainly on 23 cancers in which HRD was significantly associated with patient overall survival (OS) rates. This analysis included the mechanisms related to patient prognosis, gene expression, gene mutation, and signaling pathways. In this study, HRD was found to be significantly associated with patient prognosis, but its impact varied among different cancers. HRD was linked to different outcomes for patients with distinct tumor subtypes and was correlated with clinical features, such as clinical stage and tumor grade. Driver gene mutations, including TP53, MUC4, KRAS, HRAS, FLG, ANK3, BRCA2, ATRX, FGFR3, NFE2L2, MAP3K1, PIK3CA, CIC, FUBP1, ALB, CTNNB1, and MED12, were associated with HRD across specific cancer types. We also analyzed differentially expressed genes (DEGs) and differentially methylated regions (DMRs) in relation to HRD levels in these cancers. Furthermore, we explored the correlation between HRD and signaling pathways, as well as immune cell infiltration. Overall, our findings contribute to a comprehensive understanding of HRD’s multifaceted role in cancer.  \nKeywords: Homologous recombination deficiency (HRD), prognosis, gene mutation, DNA methylation, signaling pathway, immunology.  \nIntroduction  \nDespite rapid advancements in medical technology, cancer remains a leading global cause of mortality [1] . Recently, immunotherapy has been developed and widely used in cancer treatment, and it is considered one of the most promising strategies for cancer therapy [2–4] . For speciﬁc cancer subtypes, such as lung squamous cell carcinoma (LUSC) and bladder urothelial carcinoma (BLCA), immunotherapy has shown signiﬁcant curative eﬀects and has greatly extended patient survival rates [5, 6]. Despite these signiﬁcant advances in many cancer subgroups, the clinical application of immunotherapy still faces several challenges related to eﬃcacy and safety [7, 8], and only a small proportion of patients beneﬁt from immunotherapy [9, 10] . For instance, studies have found that anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibodies are a promising treatment for advanced gastric cancer (GC) patients, but the response rate remains limited, and it is necessary to develop new strategies to maximize the eﬃcacy of immune checkpoint inhibitors (ICIs). Therefore, further study to identify precise biomarkers to predict the eﬃcacy of  \nimmunotherapy and explore new eﬀective bio-targets for cancer therapy is both important and urgent.  \nHomologous recombination is a highly conserved process that plays an important role in DNA repair, DNA replication, meiosis, chromosome separation, and telomere maintenance [11] . Homologous recombination repair is oneof the core methods for DNA damage repair. It mainly occurs in the S and G2 phases of the cell cycle and serves as a DNA repair mechanism to maintain genome integrity, ensuring the transmission of genetic information with high ﬁdelity [12] . When DNA damage occurs and cannot be repaired normally through the homologous recombination repair process, it isclassiﬁed as homologous recombination deﬁciency (HRD) [13] . Some known genes encoding homologous recombination proteins include breast cancer 1 gene (BRCA1), breast cancer 2 gene (BRCA2), ataxia-telangiectasia mutated gene (ATM), ataxia-telangiectasia and Rad3-related gene (ATR), BRCA1-associated RING domain 1 gene (BARD1), Bloom syndrome protein ","cbCaivnbuD75JicQ","https://ap.wps.com/l/cbCaivnbuD75JicQ","pdf",2358583,11,"English","# Introduction\n## Immunotherapy challenges and biomarker need\n## Biological role of homologous recombination and HRD definition\n## HRD-related genes and clinical relevance","[{\"question\":\"What does the study aim to clarify about homologous recombination deficiency (HRD)?\",\"answer\":\"It evaluates the association between HRD and patient overall survival across multiple cancer types, addressing uncertainty in existing findings and the need for a comprehensive cross-cancer understanding.\"},{\"question\":\"Which omics layers and biological aspects are analyzed in relation to HRD?\",\"answer\":\"The analysis integrates gene expression, gene mutation, differentially methylated regions, and signaling pathway correlations, and it also examines immune cell infiltration patterns.\"},{\"question\":\"How do the effects of HRD differ across cancers and tumor subtypes?\",\"answer\":\"HRD is significantly linked to prognosis overall, but its impact varies by cancer type, and outcomes differ across tumor subtypes; HRD also correlates with clinical stage and tumor grade.\"}]","Multiomics analysis of homologous recombination deficiency across cancer types - Research focus | PDF",1790005917,28]